1 / 13

Qian Li, Sc. D.

Advisory Committee Presentation on Vioxx (Rofecoxib) Discussion on the meta analyses for cardiovascular risk assessment. Qian Li, Sc. D. Confirmed Serious CV Thrombotic Events Observed in VIGOR. 50 mg. Key Features of the Meta Analysis. Meta analysis of 25 studies

ishmael-benjamin
Download Presentation

Qian Li, Sc. D.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advisory Committee Presentation on Vioxx (Rofecoxib)Discussion on the meta analyses for cardiovascular risk assessment Qian Li, Sc. D.

  2. Confirmed Serious CV Thrombotic Events Observed in VIGOR 50 mg VIOXX

  3. Key Features of the Meta Analysis • Meta analysis of 25 studies • pooling different dose levels of rofecoxib (12.5, 25, and 50 mg) • pooling studies of different duration (4 weeks to one year) • combining different indication by stratified analyses (RA, OA, Alzheimer and back pain) VIOXX

  4. Issue of the Meta Analysis • Does the meta analysis adequately address the role of rofecoxib 50 mg in relation to CV event? VIOXX

  5. Concerns of the Meta Analysis 1. The risk ratios between rofecoxib & comparator may not be constant over time, • short term studies may not be able to demonstrate the treatment difference VIOXX

  6. Concerns of the Meta Analysis 2. The risks may not be the same for different dose levels of rofecoxib, pooling may obscure the risk associated with a high dose group. Complication occurs if • different lengths of follow-up for different dose levels • different sample sizes for different dose levels VIOXX

  7. Rofecoxib Exposure Data from Meta Analysis Data Sets VIOXX

  8. Summary of Limitations • Risk ratio is not constant over time, • Not enough data over 6 month • Inadequate sample size outside VIGOR for rofecoxib 50 mg …... • Pooling different dose levels is problematic for an evaluation of rofecoxib 50 mg VIOXX

  9. Conclusions • The meta analysis does not resolve the role of rofecoxib 50 mg in relation to the risk of CV events observed in the VIGOR trial. VIOXX

  10. Three Comparisons • Rofecoxib vs. naproxen: • include indications of RA and OA • driven by the VIGOR trial • Rofecoxib vs. non-naproxen NSAIDs: • include only OA indications • Rofecoxib vs. placebo: • include ALZ and BP indication • driven by the ALZ tirals VIOXX

  11. 12.5 mg 25 mg 50 mg Sample Sizes for Studies at Least 6-month Duration Comparator VIOXX

  12. The Assessment of CV Risk on Lower Doses of Rofecoxib • Did not show increased risk of CV events of low doses of rofecoxib in this meta analysis, • due to lack of power • due to special populations • It is not possible to draw conclusion based on this meta analysis. VIOXX

  13. Preliminary Dose-response Assessmentprovided by sponsor including studies with duration longer than 6 months This assessment suggested a trend to increase risk with rofecoxib 50 mg. VIOXX

More Related